Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.5
(0.93%)
USD 0.5
(0.93%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.27 Million USD | -45.75% |
| 2022 | 13.97 Million USD | 465.79% |
| 2021 | 2.47 Million USD | 536.6% |
| 2020 | 388 Thousand USD | -63.6% |
| 2019 | 1.06 Million USD | -4.31% |
| 2018 | 1.11 Million USD | -31.4% |
| 2017 | 1.62 Million USD | -14.26% |
| 2016 | 1.89 Million USD | 32.73% |
| 2015 | 1.42 Million USD | 28.64% |
| 2014 | 1.1 Million USD | -46.37% |
| 2013 | 2.06 Million USD | 64.34% |
| 2012 | 1.25 Million USD | -71.1% |
| 2011 | 4.35 Million USD | 18.33% |
| 2010 | 3.68 Million USD | 91.17% |
| 2009 | 1.92 Million USD | 28.02% |
| 2008 | 1.5 Million USD | 43.75% |
| 2007 | 1.04 Million USD | -9.97% |
| 2006 | 1.16 Million USD | 28.66% |
| 2005 | 903.2 Thousand USD | 31.21% |
| 2004 | 688.37 Thousand USD | 23.71% |
| 2003 | 556.42 Thousand USD | 43.77% |
| 2002 | 387.02 Thousand USD | 154.76% |
| 2001 | 151.91 Thousand USD | 18.73% |
| 2000 | 127.95 Thousand USD | -88.34% |
| 1999 | 1.09 Million USD | 265.68% |
| 1998 | 300 Thousand USD | 200.0% |
| 1997 | 100 Thousand USD | 0.0% |
| 1996 | 100 Thousand USD | 0.0% |
| 1995 | 100 Thousand USD | 0.0% |
| 1994 | 100 Thousand USD | 120.0% |
| 1993 | -500 Thousand USD | -66.67% |
| 1992 | -300 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1.22 Million USD | 16.48% |
| 2024 Q1 | 1.17 Million USD | -29.33% |
| 2023 Q1 | 2.26 Million USD | 25.04% |
| 2023 Q4 | 1.65 Million USD | 53.85% |
| 2023 Q2 | 3.09 Million USD | 36.66% |
| 2023 Q3 | 1.07 Million USD | -65.24% |
| 2023 FY | 7.58 Million USD | -45.75% |
| 2022 FY | 13.97 Million USD | 465.79% |
| 2022 Q3 | 2.76 Million USD | -36.31% |
| 2022 Q4 | 1.81 Million USD | -34.38% |
| 2022 Q1 | 5.06 Million USD | 569.44% |
| 2022 Q2 | 4.33 Million USD | -14.29% |
| 2021 Q3 | 1.21 Million USD | 285.13% |
| 2021 FY | 2.47 Million USD | 536.6% |
| 2021 Q4 | 756 Thousand USD | -37.88% |
| 2021 Q1 | 181 Thousand USD | 248.08% |
| 2021 Q2 | 316 Thousand USD | 74.59% |
| 2020 Q3 | 240 Thousand USD | 900.0% |
| 2020 FY | 388 Thousand USD | -63.6% |
| 2020 Q1 | 72 Thousand USD | -89.84% |
| 2020 Q4 | 52 Thousand USD | -78.33% |
| 2020 Q2 | 24 Thousand USD | -66.67% |
| 2019 Q1 | 111 Thousand USD | -6.72% |
| 2019 Q3 | 103 Thousand USD | -27.97% |
| 2019 Q4 | 709 Thousand USD | 588.35% |
| 2019 FY | 1.06 Million USD | -4.31% |
| 2019 Q2 | 143 Thousand USD | 28.83% |
| 2018 Q3 | 229 Thousand USD | -54.2% |
| 2018 FY | 1.11 Million USD | -31.4% |
| 2018 Q1 | 266 Thousand USD | -48.35% |
| 2018 Q4 | 119 Thousand USD | -48.03% |
| 2018 Q2 | 500 Thousand USD | 87.97% |
| 2017 Q1 | 322 Thousand USD | -56.37% |
| 2017 FY | 1.62 Million USD | -14.26% |
| 2017 Q4 | 515 Thousand USD | 25.3% |
| 2017 Q2 | 376 Thousand USD | 16.77% |
| 2017 Q3 | 411 Thousand USD | 9.31% |
| 2016 Q4 | 738 Thousand USD | 122.29% |
| 2016 Q1 | 361 Thousand USD | -10.86% |
| 2016 Q2 | 411 Thousand USD | 13.85% |
| 2016 Q3 | 332 Thousand USD | -19.22% |
| 2016 FY | 1.89 Million USD | 32.73% |
| 2015 Q1 | 301.44 Thousand USD | 36.26% |
| 2015 Q2 | 312 Thousand USD | 3.5% |
| 2015 Q4 | 405 Thousand USD | -0.74% |
| 2015 FY | 1.42 Million USD | 28.64% |
| 2015 Q3 | 408 Thousand USD | 30.77% |
| 2014 Q2 | 215.4 Thousand USD | -40.01% |
| 2014 Q3 | 312.62 Thousand USD | 45.13% |
| 2014 Q4 | 221.23 Thousand USD | -29.23% |
| 2014 Q1 | 359.06 Thousand USD | -65.41% |
| 2014 FY | 1.1 Million USD | -46.37% |
| 2013 Q3 | 346.95 Thousand USD | 1.44% |
| 2013 Q2 | 342.03 Thousand USD | 0.19% |
| 2013 Q1 | 341.39 Thousand USD | -4.59% |
| 2013 FY | 2.06 Million USD | 64.34% |
| 2013 Q4 | 1.03 Million USD | 199.16% |
| 2012 Q2 | 949.74 Thousand USD | 55.27% |
| 2012 Q1 | 611.67 Thousand USD | -62.5% |
| 2012 FY | 1.25 Million USD | -71.1% |
| 2012 Q3 | 833.81 Thousand USD | -12.21% |
| 2012 Q4 | 357.81 Thousand USD | -57.09% |
| 2011 Q3 | 1.12 Million USD | 53.89% |
| 2011 Q1 | 824.62 Thousand USD | -41.88% |
| 2011 Q2 | 730.73 Thousand USD | -11.39% |
| 2011 Q4 | 1.63 Million USD | 45.05% |
| 2011 FY | 4.35 Million USD | 18.33% |
| 2010 Q3 | 815.28 Thousand USD | 19.85% |
| 2010 Q1 | 767.12 Thousand USD | 2.37% |
| 2010 FY | 3.68 Million USD | 91.17% |
| 2010 Q2 | 680.27 Thousand USD | -11.32% |
| 2010 Q4 | 1.41 Million USD | 74.04% |
| 2009 Q1 | 296.74 Thousand USD | 4.02% |
| 2009 Q2 | 432.09 Thousand USD | 45.61% |
| 2009 Q4 | 749.34 Thousand USD | 67.64% |
| 2009 Q3 | 446.99 Thousand USD | 3.45% |
| 2009 FY | 1.92 Million USD | 28.02% |
| 2008 Q4 | 285.28 Thousand USD | -33.18% |
| 2008 Q1 | 381.01 Thousand USD | 6.27% |
| 2008 Q3 | 426.93 Thousand USD | 3.99% |
| 2008 Q2 | 410.56 Thousand USD | 7.75% |
| 2008 FY | 1.5 Million USD | 43.75% |
| 2007 Q4 | 358.52 Thousand USD | 55.1% |
| 2007 Q2 | 210.74 Thousand USD | -14.23% |
| 2007 Q1 | 245.69 Thousand USD | -48.82% |
| 2007 FY | 1.04 Million USD | -9.97% |
| 2007 Q3 | 231.15 Thousand USD | 9.69% |
| 2006 Q2 | 143.19 Thousand USD | -40.77% |
| 2006 Q4 | 480.08 Thousand USD | 61.65% |
| 2006 Q3 | 296.99 Thousand USD | 107.41% |
| 2006 Q1 | 241.74 Thousand USD | 8.69% |
| 2006 FY | 1.16 Million USD | 28.66% |
| 2005 FY | 903.2 Thousand USD | 31.21% |
| 2005 Q1 | 191.08 Thousand USD | -0.46% |
| 2005 Q2 | 249.27 Thousand USD | 30.45% |
| 2005 Q3 | 240.43 Thousand USD | -3.55% |
| 2005 Q4 | 222.41 Thousand USD | -7.5% |
| 2004 Q4 | 191.95 Thousand USD | 12.66% |
| 2004 Q1 | 130.7 Thousand USD | -48.27% |
| 2004 Q2 | 195.33 Thousand USD | 49.45% |
| 2004 Q3 | 170.38 Thousand USD | -12.78% |
| 2004 FY | 688.37 Thousand USD | 23.71% |
| 2003 Q1 | 96.62 Thousand USD | -47.24% |
| 2003 FY | 556.42 Thousand USD | 43.77% |
| 2003 Q3 | 109.87 Thousand USD | 12.92% |
| 2003 Q2 | 97.29 Thousand USD | 0.7% |
| 2003 Q4 | 252.63 Thousand USD | 129.94% |
| 2002 Q3 | 85.84 Thousand USD | 41.16% |
| 2002 Q4 | 183.13 Thousand USD | 113.33% |
| 2002 FY | 387.02 Thousand USD | 154.76% |
| 2002 Q1 | 57.23 Thousand USD | 8.3% |
| 2002 Q2 | 60.81 Thousand USD | 6.25% |
| 2001 Q2 | 29.95 Thousand USD | -8.37% |
| 2001 Q1 | 32.69 Thousand USD | -54.48% |
| 2001 Q3 | 36.41 Thousand USD | 21.56% |
| 2001 FY | 151.91 Thousand USD | 18.73% |
| 2001 Q4 | 52.84 Thousand USD | 45.12% |
| 2000 Q3 | 19.34 Thousand USD | 4.41% |
| 2000 FY | 127.95 Thousand USD | -88.34% |
| 2000 Q1 | 18.25 Thousand USD | -51.32% |
| 2000 Q2 | 18.53 Thousand USD | 1.51% |
| 2000 Q4 | 71.81 Thousand USD | 271.2% |
| 1999 Q2 | 600 Thousand USD | 50.0% |
| 1999 Q1 | 400 Thousand USD | 0.0% |
| 1999 FY | 1.09 Million USD | 265.68% |
| 1999 Q4 | 37.5 Thousand USD | -62.5% |
| 1999 Q3 | 100 Thousand USD | -83.33% |
| 1998 Q1 | 100 Thousand USD | -80.0% |
| 1998 FY | 300 Thousand USD | 200.0% |
| 1998 Q3 | 100 Thousand USD | -75.0% |
| 1998 Q2 | 400 Thousand USD | 300.0% |
| 1997 FY | 100 Thousand USD | 0.0% |
| 1997 Q1 | 100 Thousand USD | 0.0% |
| 1997 Q4 | 500 Thousand USD | 400.0% |
| 1997 Q3 | 100 Thousand USD | 0.0% |
| 1997 Q2 | - USD | -100.0% |
| 1996 Q2 | - USD | -100.0% |
| 1996 Q3 | 100 Thousand USD | 0.0% |
| 1996 Q4 | 100 Thousand USD | 0.0% |
| 1996 FY | 100 Thousand USD | 0.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1995 Q3 | -100 Thousand USD | 0.0% |
| 1995 Q4 | 100 Thousand USD | 200.0% |
| 1995 Q2 | - USD | -100.0% |
| 1995 Q1 | 100 Thousand USD | 0.0% |
| 1995 FY | 100 Thousand USD | 0.0% |
| 1994 Q1 | 100 Thousand USD | 200.0% |
| 1994 FY | 100 Thousand USD | 120.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1994 Q2 | - USD | -100.0% |
| 1994 Q4 | 100 Thousand USD | 0.0% |
| 1993 Q1 | - USD | 100.0% |
| 1993 Q3 | -100 Thousand USD | 50.0% |
| 1993 Q4 | -100 Thousand USD | 0.0% |
| 1993 FY | -500 Thousand USD | -66.67% |
| 1993 Q2 | -200 Thousand USD | 0.0% |
| 1992 Q2 | -200 Thousand USD | 0.0% |
| 1992 FY | -300 Thousand USD | 0.0% |
| 1992 Q4 | -100 Thousand USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 Q3 | - USD | 100.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 160 Thousand USD | -5071.25% |
| Ampio Pharmaceuticals, Inc. | -250 Thousand USD | 3409.6% |
| Armata Pharmaceuticals, Inc. | -29.24 Million USD | 128.296% |
| Actinium Pharmaceuticals, Inc. | -709 Thousand USD | 1266.996% |
| Azitra, Inc. | 260.45 Thousand USD | -3076.797% |
| Can-Fite BioPharma Ltd. | 743 Thousand USD | -1013.594% |
| Chromocell Therapeutics Corporation | -2.57 Million USD | 420.77% |
| Calidi Biotherapeutics, Inc. | -1.25 Million USD | 758.758% |
| CEL-SCI Corporation | -3.95 Million USD | 309.027% |
| iBio, Inc. | -1.02 Million USD | 907.22% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | -13.39 Million USD | 161.779% |
| Navidea Biopharmaceuticals, Inc. | -119.29 Thousand USD | 7035.748% |
| NovaBay Pharmaceuticals, Inc. | 7.89 Million USD | -4.801% |
| NanoViricides, Inc. | -759.01 Thousand USD | 1190.098% |
| Oragenics, Inc. | -15.45 Million USD | 153.543% |
| BiomX Inc. | -1.22 Million USD | 773.779% |
| BiomX Inc. | -1.22 Million USD | 773.779% |
| Protalix BioTherapeutics, Inc. | 42.51 Million USD | 80.537% |
| Palatin Technologies, Inc. | 4.39 Million USD | -88.369% |
| Scorpius Holdings, Inc. | -2.21 Million USD | 473.305% |